Dr. Biran Discusses Selinexor Triplet for Relapsed, Refractory MM
By Noa Biran, MD - Last Updated: January 31, 2025Noa Biran, MD of Hackensack Meridian Health reviews the results of selinexor, pomalidomide, and dexamethasone for the treatment of relapsed or refractory multiple myeloma. She also discusses how the introduction of selinexor combinations could reshape the multiple myeloma treatment landscape.
Advertisement
Post Tags:ASH 2024: Myeloma
Advertisement
Related Posts
Nirav Shah, MD, MSHP, tells BCT about his team's phase I/II clinical trial findings.
Phase 1b data suggest that continuous low-dose lenalidomide improves the therapeutic index in patients RRMM.
ISB 2001, a novel BCMA-targeting trispecific antibody, showed increased expression of T-cell activation cell surface markers.
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.